Navigation Links
Mylan Announces U.S. PTO Intends to Reissue Two Perforomist® Patents to Dey Pharma
Date:8/2/2011

BASKING RIDGE, N.J., Aug. 2, 2011 /PRNewswire/ -- Dey Pharma L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), today announced that the U.S. Patent and Trademark Office intends to reissue both of the patents related to Perforomist® (formoterol fumarate) Inhalation Solution 20 mcg/2mL vial that had been placed into reexamination by Sepracor, now known as Sunovion Pharmaceuticals. Including the two expected reissued patents, Dey believes that seven U.S. patents are infringed by Sunovion's Brovana® product. In addition, Dey believes that Teva's formotorol fumarate product pending before the FDA also infringes several of Dey's U.S. patents. The terms of the patents protecting Perforomist® extend into 2021.

Mylan Chairman and CEO Robert J. Coury commented: "We are very pleased with today's decision by the U.S. PTO in relation to intellectual property protecting Perforomist®, as well as our combination product for the treatment of Chronic Obstructive Pulmonary Disease (COPD), currently in development. We look forward to continuing to assert our very strong IP related to these products in the pending patent litigations against Sunovion and Teva. Today's developments further strengthen the potential of the Dey franchise and its portfolio of products."

About Dey Pharma

Dey Pharma, L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, severe allergic reactions and psychiatric disorders. The company puts patients first and facilitates efficient, cost-effective partnerships with customers. For more information, please visit www.dey.com.

About Mylan

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com.

Forward Looking Statements

This press release includes statements that constitute "forward-looking statements", including with regard to pending litigation, products in development and expectations for Dey's future.  These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: uncertainties inherent in legal proceedings; other legal or regulatory challenges; the impacts of competition; changes in economic and financial conditions of the company's business; and the other risks detailed in the Company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Launches First Generic Version of Entocort EC® Capsules
2. Mylan Receives Approval for Generic Version of Aricept® Tablets
3. Mylan Receives Approval for Generic Version of Effexor XR® Capsules
4. Mylan Launches Generic Version of Roxicodone® Tablets
5. Mylan Launches Generic Version of Depakote® Sprinkle Capsules
6. Mylan Launches First Generic Version of Xibrom® Ophthalmic Solution
7. Mylan Launches First Generic Version of Amrix® Capsules
8. Mylan Launches Generic Version of Risperdal® M-Tab®
9. Mylan Launches First Generic Version of Femara® Tablets
10. Mylan Launches Generic Version of Famvir® Tablets
11. Mylan Receives Approval for Generic Version of Xalatan® Ophthalmic Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016 ... ™ , la première endoprothèse à ... destinés à l,intervention portant sur les membres ... OrbusNeich, entreprise mondiale spécialisée dans ... changer la vie, a élargi son portefeuille ...
(Date:5/23/2016)... According to a new ... Product (Wheelchair, Scooters, Medical Beds, Bathroom Safety, Mechanical, ... Wound), Accessories (Lifting, Transfer) & by End User ... MarketsandMarkets, the patient handling equipment market is expected ... a CAGR of 10.5% during the forecast period ...
(Date:5/23/2016)... YORK , May 23, 2016 ... Spectrometry Market Size, Share, Development, Growth and Demand ... (Hybrid, Single and Other), by Application (Drug Discovery ... by End Users (Pharmaceuticals, Life Science and Biotechnology, ... by P&S Market Research, the global mass ...
Breaking Medicine Technology:
(Date:5/24/2016)... Los Angeles, CA (PRWEB) , ... May 24, ... ... devoted to everything egg freezing, today announced the official relaunch of its community ... to use their frozen eggs. Eggsurance's mission is to create a safe and ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... advancing the science and clinical practice of radiosurgery, is recognizing five medical residents ... radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). The awards will be presented at ...
(Date:5/24/2016)... ... 2016 , ... The number of health insurance policies sold ... last year, according to data in the forthcoming AIS’s Directory of Health Plans: ... a slight decrease in risk-based groups and a slight increase in administrative-services-only/self-funded group ...
(Date:5/24/2016)... OR (PRWEB) , ... May 24, 2016 , ... ... welcomed Peggy Kinst, a wellness specialist for forty years and a trainer for ... the Sharon Kleyne Hour Radio Talk Show on May 16, 2016. , Formerly ...
(Date:5/24/2016)... New York (PRWEB) , ... May 24, 2016 , ... WaterAid launched the ... issues faced by more than 1 billion women around the world who do not have ... thousand women from across the US about their dread of #perioddrama. The (sometimes hilarious) results ...
Breaking Medicine News(10 mins):